

ABMU Finance Dept. Performance & Finance Committee

Period 10 Data (January 2018) 21st February 2018

£794,546 overspent

In Month

£26,797,799 overspent

Forecast


£30,000,000 overspent

Туре	Cur Month Budget (£'000)	Cur Month Actual (£'000)	ctual Variance	
Income	(19,519)	(19,949)	(431)	2.21%
Pay	55,482	53,769	(1,713)	3.09%
Non Pay	56,436	59,375	2,938	5.21%
Total	92,400	92,400 93,195 79		0.86%

Туре	YTD Budget (£'000)	YTD Actual (£'000)	YTD Variance (£'000)	% Variance	
Income	(196,554)	(199,411)	(2,857)	1.45%	
Pay	539,529	539,529 530,287		1.71%	
Non Pay	539,732	578,629	38,897	7.21%	
Total	882,708	909,505	26,798	3.04%	

Cumulative

Туре	Full Year Budget (£'000)	Full Year Forecast Forecast Variance (£'000) (£'000)		% Variance
Income	-235,864	-239,293	-3,428	1.45%
Pay	Pay 647,435 6		-11,091	-1.71%
Non Pay	647,679	692,198	44,519	6.87%
Total	1,059,249	1,089,249	30,000	2.83%



Revenue	Revenue							
Financial KPIs: To ensure that net operating costs do not exceed the revenue resource limit set by Welsh Government	Value £'000	Trend						
Reported in-month financial position – deficit/(surplus) – Forecast Amber	795	I						
Reported year to date financial position – deficit/(surplus) – Forecast Red	26,798	1						
Reported year to date compared to forecast financial plan deficit — Forecast Red	1,798	1						
Current reported year end forecast – deficit/(surplus) – Forecast Amber	30,000	1						

Capital						
Capital KPIs: To ensure that costs do not exceed the Capital resource limit set by Welsh Government	Value £000	Trend				
Reported in-month financial position – deficit/(surplus) – Forecast Amber	(3,273)	1				
Current reported year end forecast – deficit/(surplus) – Forecast Green	Breakeven					

PSPP		
PSPP Target: To pay a minimum of 95% of all non NHS creditors within 30 days of receipt of goods or a valid invoice	Value %	Trend
Cumulative year to date % of invoices paid within 30 days (by number) – Forecast Red	93.7	1

Revenue Narrative

- The Health Board P10 in month overspend of £0.795m is an improvement from the £1.775m in month overspend in P10. This improvement reflects sustained improvements in operational financial performance and the continued crystallisation of corporate benefits, balance sheet/commitment release, primary care rates rebate and Hep C drugs.
- 2. The cumulative position is now £3.202m below the £30m overspend that could be anticipated based on the £36m control total.
- 3. The Health Board has reduced its year-end forecast to £30m following detailed discussions with WG.

Capital Narrative

- WG funded schemes reported as High risk –Renal £240k slippage, National Clinical Systems £163k slippage, Linac A £127k scheme underspend and HVS 1b 70k underspend. A plan for reinvestment of underspends has been submitted to WG for approval. Slippage will be managed internally by the Health Board
- In month surplus attributable to a number of schemes including those mentioned above. A plan for reallocation of some the reported underspends will be presented to the Investment Benefits Group on Monday 12th February. Other schemes will be closely monitored and reallocated if required.

PSPP Narrative


1. The number of invoices paid within 30 days continues to be below the 95% target, cumulative compliance reducing from 94.3% at the end of December to 93.7% at the end of January. This is due to In month compliance for January of only 90.04%. In month there were in excess of 3,000 invoices which failed the PSPP target with the main reasons being due to delays in the processing of nurse bank invoices (1,852), delays in receipting of orders (719) and delays in authorisation of manual invoices (487). It is now unlikely that 95% compliance for the full year will be achieved as this will require compliance rates of around 98% to be achieved in February and March.


		In Mth					YTD	YTD
	Budget £'000	Actual £'000	Variance £'000	Variance %	Budget £'000		Actual £'000	
ervice Delivery Units								
ingleton	12,404	12,955	551	4.44%	118,726		124,045	124,045 5,319
OW	8,862	8,903	41	0.46%	84,313	l	86,174	86,174 1,861
lorriston	18,312	19,018	706	3.86%	172,814	l	182,311	182,311 9,497
1ental Health & LD	9,769	9,552	216	-2.21%	94,934		93,172	93,172 - 1,762
C& Community	20,558	20,326	- 232	-1.13%	200,095		200,124	200,124 29
PT Unit	15,096	14,960	- 137	-0.90%	146,409		145,904	145,904 - 505
ıb Total Units	85,000	85,713	713	0.84%	817,290		831,729	831,729 14,439
irectorates								
oard Secretary	390	405	16	4.06%	3,852		3,883	3,883 31
Director of Strategy	16,975	17,287	313	1.84%	170,022		171,816	171,816 1,794
Director of Therapies & Health Sciences	54	52	1	-2.42%	489		482	482 - 7
inance	444	443	1	-0.15%	4,918		4,929	4,929 10
nformatics	1,157	1,023	134	-11.55%	10,643		10,839	10,839 195
Medical Director	200	160	40	-19.85%	1,821		1,571	1,571 - 250
lursing Director	324	284	40	-12.47%	3,068		2,979	2,979 - 90
Vorkforce & OD	441	428	- 14	-3.13%	4,379		4,439	4,439 60
ub Total Directorates	19,984	20,083	99	0.50%	199,193		200,938	200,938 1,745
elegated Budget Position	104,984	105,796	812		1,016,484		1,032,667	1,032,667 16,184
orporate Plan	- 104,984	- 105,002	- 17		- 1,016,484		1,005,870	1,005,870 10,614
ealth Board Position	-	795	795	-	-		26,798	26,798 26,798

In month position has further improved. The key reasons for improvement are:

- Actual pay costs have increased but this is offset by the planned winter pressures investment and variable pay is lower in Mth 10 than Mth 9.
- Non Pay costs have been maintained in most areas with the exception of Secondary Care Drugs.
- Expenditure across both pay and non pay was expected to increase from the Month 10 position as we move through Q4.

Savings Analysis





Narrative

- The Recovery Action Plan has been translated into the saving trackers, enabling the savings requirement to be fully identified, removing black (unidentified) schemes.
- The level of Green and Amber schemes has increase as delivery confidence improves for a range of schemes.


Narrative

- The level of savings delivery in January has increased from that of the previous months.
- This delivery is continuing to be monitored closely through the Financial Recovery meetings.
- The delivery failure of the Red schemes has been mitigated by other opportunities and actions, many of which are non-recurrent and it is essential that the Red schemes continue to be driven to ensure full delivery from April 2018.


Savings by Executive Stream

Health Board View By Theme of Planned Savings

Capacity Redesign	Patient Flow	Workforce Medical	Workforce	Theatres	Back Office & Estates	Procurement	Out Patients	Medicines Mangt	GAP
£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's	£000's




<u>@ P10</u>	Total Plan £000	YTD Plan £000	YTD Delivery £000	YTD Variance £000
Capacity Redesign	£5,042	£3,838	£3,203	-£635
Patient Flow	£0	£0	£0	£0
Workforce Medical	£1,148	£748	£499	-£249
Workforce	£9,995	£6,954	£3,147	-£3,807
Theatres	£650	£475	£439	-£36
Back Office & Estates	£1,803	£1,219	£371	-£848
Procurement	£4,370	£3,527	£2,907	-£620
Out Patients	£0	£0	£0	£0
Medicines Mangt	£2,740	£2,525	£2,660	£135
TOTAL	£25,000	£19,286	£13,226	-£6,060




Health Board - Pay Position




- Up to P06 the monthly pay expenditure for the P02-P06 months was higher than the average for 16/17, this reduced in P07-P09 but has increased in P10 as anticipated linked to Winter Pressures.
- Whilst overall pay bill increased in P10 the variable pay costs in P10 decreased below the P09 position but above the levels seen in P06-P08. Again this increase is a reflection of the investment to support Winter Pressures.






- The A&C Vacancy Control panel has halted this growth and A&C numbers are now reducing on a month by month basis. This reduction is being supported by the revised deployment policy.
- During this year the A&C variable pay and total paybill has also reduced.


A&C WTE MOVEMENT BY AREA P1-09 17/18 8 mananana **** 2 ** mani -3 -3 -5 -3 -15 -16









Other Non Pay



- Secondary Care drugs expenditure increased in P10 due to increasing activity levels
- Primary Care drugs had increased due to Cat M and NCSO price concessions. This area continues to be a potential risk to the organisation, however the scale of the risk is reducing.
- ChC/FNC the increase in P07 reflected the inflationary uplift paid in P07 backdated to April.
- Other non pay has held well.
 Some of the increases seen in P4-5 are due to changes in accounting practice for expenditure that has previously been reported in P12, giving an artificial expenditure spike.





Narrative

- Following confirmation of cash support from Welsh Government of £32.128m of repayable strategic cash assistance and non repayable cash support of £11.221m for movement in working balances the health board is no longer forecasting a cash deficit.
- 2. The heath board is planning for a year end cash balance of £0.5m. Based on the latest receipts and payment trends and the reduction in the forecast I&E deficit to £30m the current forecast is that of a year end cash balance of £6.498m if the full amount of strategic cash assistance is drawn down in cash from Welsh Government.
- 3. Given the forecast cash balance it is probable that the health board will not require the full amount of strategic cash assistance available from Welsh Government and Welsh Government will be advised in the January monitoring returns submission that it is probable that the health board will not be drawing down £5.5m of the available strategic cash assistance.
- 4. The cash position will continue to be monitored daily with Welsh Government requesting confirmation of the final amount of cash to be drawn down at the beginning of March.

Winter Pressure Plan

	Agreed Funding £000	Anticipated Spend £000
Initial Winter Plan	500	500
Support to Sustain Elective Capacity	823	711
Additional Winter Schemes	1,701	1,839
Total	3,024	3,050

Winter Pressure Plan

- Winter Pressures financial assumptions are made up of three elements;
 - the initial winter plan funding £0.5m,
 - support to sustain elective capacity from Performance monies £0.823m,
 - Winter Pressures funding allocated by WG £1.701m
- The initial winter plan funding of £0.5m, enabled a range of schemes to be agreed. The costs reflected a 3 month time period. Some of the funding has been utilised earlier than plan and the impact of continuing to the end of the financial year, will be met through seasonal pressures funding.
- Two schemes to sustain elective capacity were agreed, Theatre Admissions Unit and additional Critical Care capacity.
- The additional winter pressures funding allocated by WG has been utilised for a wide range of schemes in secondary care, community and primary care. Schemes in excess of the £1.7m were identified, however due to implementation slippage, the likely costs are not significantly above the funding available.

RTT Funding Available

		£000
Internal Funding for Q1		1,000
WG Performance Support		10,070
Less TAU	-	573
Less Critical Care	-	250
		10,247
Spend to Date	-	5,586
Remaining Allocation		4,661

Narrative - RTT

- The funding available for RTT from WG performance monies and internal resources is £10.247m.
- The expenditure to date amounts to £5.586m.
- There remains £4.661m to enable the delivery of the agreed RTT target during the final two months of the year.
- The Health Board has indicated to WG that it is unlikely to be in a position to spend around £2m-£3m of this RTT funding. This is not reflected in the financial forecast as we are expecting a funding claw back of a similar amount for not achieving the target of no more than 2640 patients waiting over 36 weeks.

RTT Spend @ End P10

Q1 Spend	Q2 Spend	P7 Spend	P8 Spend	P9 Spend	P10 Spend	Total Spend
205 664	210 662	190 762	122 241	101 150	442.670	1 452 260
295,004	219,003	180,763	123,341	191,158	442,679	1,453,268
295,649	213,794	186,330	73,413	151,918	402,513	1,323,617
137,099	110,588	41,464	40,489	44,120	39,079	412,839
						3,189,724
720,412	J-1,0-1J	400,337	237,243	307,130	004,271	3,103,724
Q1 Spend	Q2 Spend	P7 Spend	P8 Spend	P9 Spend	P10 Spend	Total Spend
88,317	457,610	244,119	312,100	287,546	224,504	1,614,196
-	-	88,334	166,540	88,334	64,612	407,820
-	-	134.412	47.712	85.452	106.568	374,144
		20 1) 122	.,,,,,,,	33) 132	200,000	<u> </u>
88,317	457,610	466,865	526,352	461,332	395,684	2,396,160
Q1 Spend	Q2 Spend	P7 Spend	P8 Spend	P9 Spend	P10 Spend	Total Spend
383.981	677.273	424.882	435.441	478.704	667.183	3,067,464
000,000	,	,,,,,,,,	100/112		001,200	
295,649	213,794	274,664	239,953	240,252	467,125	1,731,437
137,099	110,588	175,876	88,201	129,572	145,647	786,983
816,729	1.001.655	875.422	763,595	848,528	1,279,955	5,585,884
	295,664 295,649 137,099 728,412 Q1 Spend 88,317 88,317 Q1 Spend 383,981 295,649 137,099	295,664 219,663 295,649 213,794 137,099 110,588 728,412 544,045 Q1 Spend Q2 Spend 88,317 457,610	295,664 219,663 180,763 295,649 213,794 186,330 137,099 110,588 41,464 728,412 544,045 408,557 Q1 Spend Q2 Spend P7 Spend 88,317 457,610 244,119 - - 88,334 - - 134,412 88,317 457,610 466,865 Q1 Spend Q2 Spend P7 Spend 383,981 677,273 424,882 295,649 213,794 274,664 137,099 110,588 175,876	295,664 219,663 180,763 123,341 295,649 213,794 186,330 73,413 137,099 110,588 41,464 40,489 728,412 544,045 408,557 237,243 Q1 Spend Q2 Spend P7 Spend P8 Spend 88,317 457,610 244,119 312,100 - - 88,334 166,540 - - 134,412 47,712 88,317 457,610 466,865 526,352 Q1 Spend Q2 Spend P7 Spend P8 Spend 383,981 677,273 424,882 435,441 295,649 213,794 274,664 239,953 137,099 110,588 175,876 88,201	295,664 219,663 180,763 123,341 191,158 295,649 213,794 186,330 73,413 151,918 137,099 110,588 41,464 40,489 44,120 728,412 544,045 408,557 237,243 387,196 Q1 Spend Q2 Spend P7 Spend P8 Spend P9 Spend 88,317 457,610 244,119 312,100 287,546 - - 88,334 166,540 88,334 - - 134,412 47,712 85,452 88,317 457,610 466,865 526,352 461,332 Q1 Spend Q2 Spend P7 Spend P8 Spend P9 Spend 383,981 677,273 424,882 435,441 478,704 295,649 213,794 274,664 239,953 240,252 137,099 110,588 175,876 88,201 129,572	295,664 219,663 180,763 123,341 191,158 442,679 295,649 213,794 186,330 73,413 151,918 402,513 137,099 110,588 41,464 40,489 44,120 39,079 728,412 544,045 408,557 237,243 387,196 884,271 Q1 Spend Q2 Spend P7 Spend P8 Spend P9 Spend P10 Spend 88,317 457,610 244,119 312,100 287,546 224,504 - - 88,334 166,540 88,334 64,612 - - 134,412 47,712 85,452 106,568 88,317 457,610 466,865 526,352 461,332 395,684 Q1 Spend Q2 Spend P7 Spend P8 Spend P9 Spend P10 Spend 383,981 677,273 424,882 435,441 478,704 667,183 295,649 213,794 274,664 239,953 240,252 467,125 137,099